Trading Update
Summary by AI BETAClose X
4 February 2026
Futura Medical plc
("Futura", "the Group" or the "Company")
Trading Update
Futura Medical (AIM: FUM), the consumer healthcare Group behind Eroxon® and that specialises in the development and global commercialisation of innovative and clinically proven sexual health products, is pleased to provide an unaudited trading update for the year ended 31 December 2025 (FY25).
The Company now expects to deliver FY25 revenue of £1.7 million, ahead of previously guided management expectations*. Additionally, net cash at year end was £3.4 million following the successful £2.75 million fundraise in November 2025. As previously announced, under the Company's existing agreement with Haleon and subject to the granting of a U.S. patent for Eroxon, the Company expects to trigger a milestone payment from Haleon of US$2.5 million during H1 2026; in addition, the Company expects to receive a tax credit refund for FY2025 of approximately £0.3 million.
The Company's existing cash resources including the net proceeds of the fundraise in November 2025, combined with the expected tax credit refund for the 2025 financial year, the US patent milestone payment from Haleon and proceeds from ongoing sales of Eroxon, are expected to provide the Company with a cash runway to December 2026, which is in line with prior statements.
As previously announced, the Board is undertaking a strategic review of the business and its operations which is expected to conclude in Q1 2026. The outcomes of the review will be published in the Company's Full Year Results which are expected to be released mid-April 2026.
*On 19th September 2025, the Company disclosed that it expected to deliver revenue between £1.3 million and £1.4 million for FY25
The information communicated in this announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014 as amended by the Market Abuse (Amendment) (EU Exit) Regulations 2019.
Contacts:
|
Futura Medical plc
|
Alex Duggan Chief Executive Officer Angela Hildreth Finance Director and COO
|
investor.relations@futuramedical.com +44 (0)1483 685 670
|
|
Panmure Liberum Nominated Adviser and Broker |
Emma Earl, Will Goode, Mark Rogers (Corporate Finance)
|
+44 (0)20 3100 2000
|
|
|
|
|
|
Turner Pope Investments (TPI) Ltd - Broker |
Guy McDougall, Andrew Thacker |
+44 (0) 20 3657 0050 |
|
|
|
|
|
Alma Strategic Communications |
Rebecca Sanders-Hewett, Sam Modlin, Sarah Peters |
+44 (0)20 3405 0205 futura@almastrategic.com |
|
|
|
|
Notes to Editors:
Futura Medical plc (AIM: FUM) is the developer of innovative sexual health products, including lead product Eroxon® and development products WSD4000 and Eroxon® Intense. Our core strength lies in our research, development and commercialisation of topically delivered gel formulations in sexual health products.
Sexual health issues are prevalent in both men and women. Erectile Dysfunction ("ED") impacts 1 in 5 men globally across all adult age brackets, with approximately half of all men over 40 experiencing ED and 25% of all new diagnoses being in men under 40. Around 60% of women experience at least one symptom of sexual dysfunction, and only one in four women seek professional help, and remain chronically underserved.
Eroxon®, Futura's clinically proven lead product, has been developed for the treatment of ED. The highly differentiated product, which is the only topical gel treatment for ED available over the counter and helps men get an erection in ten minutes, addresses significant unmet needs in the ED market. Eroxon® has been nominated for a number of healthcare industry awards and has won two to-date. Multiple distribution partnerships are in place for Eroxon, across major consumer markets.
The WSD4000 is a prototype product designed for the symptoms of impaired sexual response and function in women. There is currently no regulatory approved OTC treatment available for impaired sexual response and function in women. WSD4000 has the potential to be an effective, breakthrough treatment for the common symptoms associated with impaired sexual response and function, such as lack of desire, arousal and lubrication.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 1 day ago Savannah Energy
- 1 day ago Buccaneer Energy PLC
- 1 day ago Savannah Energy
- 1 day ago Carclo
- 1 day ago Schroder Japan Growth Fund